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Abstract
Introduction: Cutaneous lupus erythematosus (CLE) is a chronic disease characterized by disfigurement and a
relapsing course. Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not
exempt from significant side effects and frequent relapses after withdrawal. New thalidomide analogues have been
developed but lack clinical experience. The aim of this preliminary phase II study was to evaluate the efficacy and
safety of lenalidomide in patients with refractory CLE.
Methods: Fifteen patients with refractory cutaneous lupus disease were enrolled in this single-center, open-label,
non-comparative pilot trial between January 2009 and December 2010. Oral lenalidomide (5 to 10 mg/day) was
administered and tapered according to clinical response. Patients were followed up for a mean of 15 months
(range: 7 to 30). Primary efficacy endpoint was the proportion of patients achieving complete response, defined by
a Cutaneous Lupus Erythematosus Disease Area and Severity index (CLASI) activity score of 0. Other secondary
endpoints included development of side effects, evaluation of cutaneous and systemic flares, and impact on the
immunological parameters.
Results: One patient discontinued treatment due to side effects. All remaining patients saw clinical improvement
and this was already noticeable after 2 weeks of treatment. Twelve of those patients (86%) achieved complete
response but clinical relapse was frequent (75%), usually occurring 2 to 8 weeks after lenalidomide’s withdrawal. No
influence on systemic disease, immunological parameters or CLASI damage score was observed. Side effects
including insomnia, grade 2 neutropenia and gastrointestinal symptoms, were minor (13%). These resolved after
withdrawing medication. Neither polyneuropathy nor thrombosis was observed.
Conclusion: Lenalidomide appears to be efficacious and safe in patients with refractory CLE, but clinical relapse is
frequent after its withdrawal.
Trial registration: ClinicalTrials.gov: NCT01408199.
Introduction
Cutaneous involvement in lupus erythematosus disease is
common, largely heterogeneous and characterized by a
chronic relapsing course [1-3]. As many as 70 to 80% of
patients will develop skin lesions at some point during
the course of their disease, with a significant proportion
being disfiguring and debilitating [1]. Although most
patients respond to the standard first-line therapy of
topical steroids and antimalarials, approximately 30 to
40% of cases will be refractory to these regimens. For this
significant minority, there is no consensus algorithm and
a trial and error approach using multiple systemic agents
has shown a variable poor response [4-6].
Thalidomide, a glutamic acid derivative, is an agent with
a mechanism of action that includes both tumoricidal and
immunomodulatory effects. It was first synthesized in
1954 and widely used as a sedative agent, but had to be
withdrawn from the market after teratogenic and neurolo-
gic effects were established [7]. In recent years, there has
been a renewed interest in its use, and currently is also
prescribed in various oncologic, dermatologic, and inflam-
matory conditions, including refractory cutaneous lupus
erythematosus (CLE) [8]. In the latter, a significant rapid
clinical response has been reported in 80 to 90% of the
treated patients [8-17]. However, despite its effectiveness,
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sustained long-term remission after its withdrawal is low,
relapse occurs frequently and it is not exempt from severe
side effects that are the main limitation on its continued
use [17].
Given thalidomide’s vast clinical potential to treat
inflammatory and neoplastic conditions, efforts in the
mid-1990s led to the development of a promising thali-
domide analogue, lenalidomide (CC-5013 or Revlimid™),
to improve tolerability and efficacy over the parent drug.
In recent years, lenalidomide (5 to 50 mg/day) has been
most extensively studied and approved for refractory/
relapsing multiple myeloma and myelodysplastic syn-
dromes [18,19].
Thalidomide and its immunomodulatory analogues
(IMiDs), first established as agents with antiangiogenic
properties, inhibit the production of cytokines (TNF-a),
interleukins (IL) 1b, 6, 12 and TNF-a-induced cell sur-
face adhesion molecules (ICAM-1, VCAM-1, E-selectin).
In addition, they promote apoptosis, and increase the
NK-dependent cytotoxicity by altering natural killer (NK)
cell numbers and function [20]. Although both IMiDs
have demonstrated similar biological activities, lenalido-
mide is more potent than thalidomide and therefore
achieves responses at lower doses [20-22]. Lenalidomide
has also been shown to have a different toxicity profile.
Whereas somnolence, constipation and peripheral neuro-
pathy have been less reported [21], myelosuppression
occurs more frequently in a dose-independent manner
[18,20-22].
Thus, based on its immunomodulatory properties, the
favorable toxicity profile and its potential superior effi-
cacy compared to the parent drug, lenalidomide may be
an alternative in refractory inflammatory dermatosis such
as cutaneous lupus. So far, there is little familiarity with
its use in this field and only a small number of patients
have been treated with lenalidomide (5 to 10 mg/day)
albeit with encouraging results [23,24]. Given the limited
clinical experience, its potential beneficial effects and the
need to better understand its effect on the systemic facet
of the lupus disease, a larger open phase II trial was
initiated.
Materials and methods
Study design
The purpose of this open-labelled, single centre, phase II
pilot study was to establish the efficacy and safety of lenali-
domide in refractory CLE. The study protocol was
approved by the local research ethics committee of Vall
d’Hebron Hospital and was conducted according to ICH
good clinical practice and in accordance with the Declara-
tion of Helsinki. All patients gave their written informed
consent. The study was registered at the ClinicalTrials.gov
(Identifier: NCT01408199).
Endpoints
The efficacy primary endpoint was the proportion of
patients achieving complete response. Clinical response
was evaluated by the validated Cutaneous Lupus Erythe-
matosus Disease Area and Severity Index (CLASI) [25].
Response was defined as follows: complete response (CR)
as a complete resolution of the inflammatory rash (CLASI
activity score = 0); partial response (PR) by at least a 50%
improvement in the CLASI score by week 12 when com-
pared to baseline, and no response when no improvement
or worsening in the CLASI score was observed at the
same time period.
Secondary endpoints included the proportion of
patients: developing any adverse event (AE); having a
cutaneous relapse, defined as a new CLASI ≥ 4 in those
who previously achieved CR following treatment withdra-
wal; developing a systemic lupus flare, assessed by the
Systemic Lupus Erythematosus Disease Activity Index
2000 (SLEDAI) [26] in which a mild flare was defined as
a change in SLEDAI score greater than 3 and a severe
flare by a change in SLEDAI greater than 12; having an
increment in the CLASI damage score [25] compared to
baseline or having an increment of anti-dsDNA antibody
titres.
An AE was defined as any adverse deviation from the
patient’s baseline condition during the trial. The events
were categorised as mild, moderate or severe. A serious AE
(SAE) was defined as an event that was life-threatening,
resulted in death, required or prolonged hospitalisation or
resulted in persistent or significant disability/incapacity.
Reasons for discontinuing treatment were: common
toxicity criteria grade 3 myelosuppression, withdrawal of
consent by the patient, pregnancy, life-threatening compli-
cations, severe systemic lupus flare requiring alternative
treatment or decision by the physician that discontinua-
tion was in the patient’s best interest.
Inclusion criteria
Patients were recruited from a single centre between Jan
2009 and 2010 according to the following eligibility criteria:
aged over 18 years; histological proven CLE with or with-
out associated systemic lupus erythematosus (SLE) disease
diagnosed according to the American College of Rheuma-
tology (ACR) SLE classification criteria [27]; presence of at
least a grade II erythema as assessed by the CLASI activity
score [25]; stable prednisone (< 10 mg/day), antimalarial,
or immunosuppressive regimens for at least 30 days before
the inclusion; refractoriness to at least 3 months of conven-
tional treatment with antimalarials and topical steroids;
and finally, at least one of, an involvement of more than
18% of the body surface area calculated according to the
‘rule of the nines’, a history of severe thalidomide side
effects or lack of efficacy following thalidomide therapy.
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For all patients, there was no known hypersensitivity to
thalidomide. Women were excluded from the study if
pregnant, lactating or not using adequate contraception.
Other key exclusion criteria included active SLE requiring
systemic immunosuppressive agents, presence of severe
thrombocytopenia (< 30,000/mm3), leukopenia (< 2,000/
mm3) or neutrophil counts below 1,000/μl, known at least
30 days prior to inclusion; previous history of arterial/
venous thrombosis; presence of antiphospholipid antibo-
dies; moderate to severe renal impairment (FG < 30 ml/
min/1.73 m2) and/or progressive renal disease. Psychiatric
or social disorder that might interfere with the follow-up
or treatment compliance, HIV or viral hepatitis infections
were also exclusion criteria. All patients gave written
informed consent prior to participation in the study.
Treatment protocol and assessment
Lenalidomide was started at 5 mg/day for 4 weeks. At that
time, if no clinical improvement was observed, using the
criteria specified before, dose was increased to 10 mg/day.
Otherwise, lenalidomide was sustained at 5 mg/day in case
of partial response or decreased progressively monthly
until its withdrawal if complete response was achieved. No
changes in concomitant baseline medication were allowed.
At entry, patients had a complete medical history
review and physical examination, including a detailed
neurological assessment. At baseline measurements of
full blood counts and immunological parameters (anti-
dsDNA, complement, antinuclear antibodies (ANA),
anti-extractable nuclear antigen (ENA) and antiphospho-
lipid antibodies) were performed. The evaluation of each
patient’s rash took into account the initial extension,
activity and degree of scarring as assessed by the CLASI
score [25]. This score consists of two separate scores: the
activity score, which reflects erythema and scaling; and
the damage score, which documents scarring and perma-
nent dyspigmentation.
Patients were followed-up monthly for the first
6 months and every three months afterwards, unless clini-
cally required. At each visit, clinical parameters including
a detailed neurological examination, the CLASI score,
response to therapy, and occurrence of side effects were
evaluated. Nerve conduction studies were performed in
those patients with previous thalidomide-induced neuro-
pathy or when new neurological symptoms occurred.
Laboratory tests (WBC) were performed weekly for the
first 2 months and then monthly following drug safety
recommendations. Exacerbations of systemic disease dur-
ing follow-up were evaluated by the SLEDAI score [26].
Statistical analysis
Statistical analysis was performed using SPSS version 7.5
(SPSS, Inc., Chicago, IL, USA). Descriptive statistics are
reported as frequency and percentage for categorical
variables and as mean and standard deviation for con-
tinuous variables. Categorical and continuous data were
compared by means of the t test and Mann-Whitney
test, as appropriate. The level of statistical significance
was set at P < 0.05.
Results
Baseline patient characteristics
Fifteen consecutive patients with refractory CLE were
included. The major subtypes of the recruits were discoid
lupus erythematosus (DLE) (60%), lupus profundus (13%)
and subacute cutaneous lupus erythematosus (SCLE)
(13%). Table 1 shows baseline clinical and serological
data. Fourteen of them had been previously treated with
thalidomide and either did not respond (n = 4) and/or
developed severe side effects (n = 11). Four patients also
had a rash covering more than 18% of the body surface
area. All patients were female and of Caucasian origin.
Age varied between 28 and 53 with a median age of 40
years. Six patients (40%) had an associated systemic dis-
ease, of whom five had positive anti-dsDNA antibodies.
Photosensitivity was present in seven patients (47%). The
mean (± SD) CLASI activity and damage scores at entry
were 11 ± 5.9 and 2.33 ± 2.96, respectively. Initial SLE-
DAI score was 3.26 ± 2.22.
Clinical efficacy
Clinical response and lenalidomide dosage are shown in
Table 2 and Figure 1. One patient discontinued the study
after 1 week due to disabling gastrointestinal side effects
(patient number 3). Clinical response (combined com-
plete and partial response) was observed in all of the
remaining patients (100%) (Figure 1), of whom 12 (86%)
achieved a CR. Four of the responders had previously
failed thalidomide therapy. A significant clinical improve-
ment was already noticeable at 2 weeks (CLASI activity
decreased from 11 ± 5.9 to 4.13 ± 3.66, P = 0.0009). Time
to CR in those patients with DLE and SCLE was shorter
and ranged from 2 to 12 weeks with a median time of 6
weeks. However, in those with lupus profundus, time to
CR varied from 4 to 32 weeks with a median time of 13
weeks. At the end of follow-up, two patients (14%)
remained in partial response, despite increasing the dose
in one case (10 mg/day). Overall, treatment duration ran-
ged from 3 to 30 months with a median of 11 months.
Patients were followed up for a median of 15 months
(range: 7 to 30). Of the twelve patients who achieved com-
plete response, nine (75%) relapsed within 2 to 8 weeks
(median 4.4), while reducing medication or after its with-
drawal. The lowest dose of lenalidomide at which relapse
occurred was 5 mg on alternate days or three times
weekly. Five patients had at least two relapses when
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Table 1 Patient demographics and clinical characteristics.
Patient
number
Sex Diagnosis Site
involvement
Reason for inclusión ANA/dsDNAa
antibodies
Anti-Ro/SSA/La/SSB
antibodies
CLASI
A/D
Previous received
treatment
1 F DLE (L) V-neck, arm T lack of efficacy, PN 1/640 (123) +/- 6/2 TCS, OCS, HCQ, T
2 F Lupus
Profundus
Arm, back T lack of efficacy 1/160 (-) -/- 7/1 TCS, OCS, HCQ, T
3 F DLE (L) Arm T lack of efficacy 1/640 (-) -/- 3/1 TCS, OCS, HCQ, T
4 F ACLE Face, v-neck T side effects 1/640 (54) -/- 6/0 TCS, OCS, HCQ, T,
AZA,
5 F Lupus
Profundus
Scalp, face, arms T side effects 1/640 (144) -/- 19/6 TCS, OCS, HCQ,
MMF, T
6 F SCLE Face, v-neck,
back
> 18% body surface 1/640 (-) +/- 19/0 TCS, OCS, MMF
7 F SCLE Face, v-neck,
hands, arms
T side effects, PN, > 18%
body surface
1/640 (83) -/- 20/1 TCS, OCS, HCQ,
AZA, T
8 F DLE (L) Face, scalp, ear
lobe
T side effects 1/40 (-) -/- 9/0 TCS, OCS, HCQ, T
9 F DLE (G) Face, ear lobe,
arms, neck
> 18% body surface, T
side effects
1/320 (37) -/- 13/2 TCS, OCS, HCQ,
MMF, T
10 F LET Face T side effects, PN 1/640 (-) -/- 6/0 TCS, HCQ, T
11 F DLE (G) Face, scalp, back T side effects, > 18%
body surface
1/40 (-) +/- 15/9 TCS, OCS, HCQ, T
12 F DLE (G) Face, v-neck,
back, scalp
T side effects, PN 1/40 (-) +/- 17/8 TCS, OCS, HCQ, T
13 F DLE (L) Face T lack of efficacy 1/160 (-) -/- 3/0 TCS, HCQ, T
14 F DLE (G) Face, v-neck T side effects 1/640 (-) -/- 11/2 TCS, OCS, HCQ,
MMF, T
15 F DLE (L) Face, scalp T side effects 1/40 (-) -/- 10/3 TCS, OCS, HCQ, T
aNormal value of anti-dsDNA antibodies is < 15 IU/ml. A, activity; ACLE, acute cutaneous lupus erythematosus; ANA, antinuclear antibodies; AZA, azathioprine;
CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; D, damage; DLE, discoid lupus erythematosus; G, generalized; HCQ, hydroxychloroquine;
L, localized; LET, lupus erythematosus tumidus; MMF, mycophenolate mofetil; OCS, oral corticosteroids; PN, polyneuropathy; SCLE, subacute cutaneous lupus
erythematosus; T, thalidomide; TCS, topical steroids.
Table 2 Summary of clinical response.
Patient
number
Clinical
outcome
Time to complete response
(weeks)
Follow-up period
(months)
Maximun dose received
(mg)
Relapse Dose at relapse
1 CR 10 15 5 Yes 5 mg twice weekly
2 CR 4 12 5 Yes 5 mg three times
weekly
3 Withdrawn - - 5 - -
4 CR 3 12 5 Yes 5 mg alternate days
5 CR 36 19 5 - -
6 CR 4 17 5 No -
7 CR 11 18 5 No -
8 CR 2 7 5 Yes 5 mg alternate days
9 PR - 15 10 - -
10 CR 7 10 5 Yes 5 mg alternate days
11 CR 4 30 5 Yes 5 mg twice weekly
12 CR 4 25 5 Yes 5 mg alternate days
13 PR - 8 5 - -
14 CR 12 17 5 Yes 5 mg three times
weekly
15 CR 2 10 5 Yes 5 mg alternate days
CR, complete response; PR, partial response.
Cortés-Hernández et al. Arthritis Research & Therapy 2012, 14:R265
http://arthritis-research.com/content/14/6/R265
Page 4 of 9
A.             B.                                                           

 
 
C.                                                                               D. 

 


 
    E.                                                                         F. 
                               
Figure 1 Clinical responses to lenalidomide therapy. Discoid lupus erythematosus (patient number 12) on upper back before (A) and after
3 months of lenalidomide therapy (5 mg/d) (B). Resolution of the erythema with persistent residual hypopigmentation and some degree of
scarring, already existing at baseline from previous cutaneous involvement. Widespread discoid lupus erythematosus (DLE) (patient number 9)
involving nose and malar area before (C) and after three months of therapy (D) resulting in a partial improvement of the erythema and
increased hypopigmentation. Widespread subacute cutaneous lupus erythematosus (SCLE) (patient number 6) involving face and V-neck area
before (E), and complete resolution after 6 weeks of lenalidomide therapy (F). All patients concerned gave their written consent for the
publication of the images.
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reducing dose and received two cycles of treatment. All
patients responded to the introduction of lenalidomide.
Three of the fourteen treated patients (21%) required a
long-term maintenance dose. Only two patients, both with
SCLE, obtained a sustained remission after withdrawing
medication.
After one year follow-up, although a slight increment
in the CLASI damage score was observed compared with
baseline (3.08 ± 3.15 vs. 2.39 ± 2.96, respectively, P =
0.398), this was not statistically significant (Figure 2).
Effect on systemic disease
Clinically, only one of the seven patients (14%) with asso-
ciated SLE developed arthralgias and mild arthritis during
follow-up (patient number 1). None of the patients with
only cutaneous lupus developed systemic symptoms. No
significant changes in the mean SLEDAI score were
observed during follow-up. Two patients had previous his-
tory of lupus nephritis. No new onset or increase in protei-
nuria was observed. When the impact of lenalidomide was
evaluated on the immunological parameters, anti-dsDNA
titres did not experience significant changes in patients
with or without previous anti-dsDNA antibodies. No effect
was observed in complement levels (C3 and C4) either
(Figure 3).
Toxicity
Generally, lenalidomide was well tolerated. Only two
patients developed side effects (13%) (Table 3). Patient
number 3, one week after medication was initiated,
developed severe vomiting, diarrhoea and weight loss
that improved after medication was withdrawn and no
other factors accounting for this episode were found.
Patient number 15 developed insomnia and grade 2 neu-
tropenia (33% neutrophils (1.190/mm3)), 2 months into
the study while on lenalidomide 5 mg/day. There was no
evidence that somnolence was a problem for patients tak-
ing the study drug. None of the patients complained of
paraesthesia. A repeated electrophysiological study in
those patients with previously known thalidomide-
induced neuropathy was performed. No worsening was
observed. No other evidence of haematological or bio-
chemical toxicities was observed. There were no throm-
botic events or ovarian toxicity during the study.
Discussion
The purpose of this trial was to investigate the efficacy
and safety of lenalidomide, a new thalidomide analogue,
in the treatment of refractory CLE. Although in recent
years there has been a better understanding of the patho-
physiological mechanisms involved in the development
of CLE, there has not been a great breakthrough in its
treatment. So far, no medication has been approved spe-
cifically for this condition and few randomized, placebo-
controlled trials, evaluating mainly topical agents in
patients with DLE, have been performed [28-30]. Cur-
rently, the first-line therapy consists of antimalarials and
topical steroids, but for refractory cases there is no con-
sensus, and in most cases, off-label systemic agents
licensed for SLE and other immunological diseases are
administered.
Thalidomide is one of the few agents with proven effi-
cacy for refractory CLE according to case reports and
observational studies [9-17]. However, despite its effec-
tiveness, its use has been limited due to its toxicity pro-
file and the current restricted availability. This trial was
encouraged by the partial beneficial effects initially pub-
lished in two patients with recalcitrant DLE who had
been treated with lenalidomide (5 to 10 mg/day) [23]
and by our experience using thalidomide in this condi-
tion [13,17]. After excluding the patient with disabling
side effects, we included a total of 14 patients with
refractory CLE. All patients experienced clinical
improvement. Complete response was achieved by 86%
of them within 2 to 12 weeks after starting lenalidomide.
This rate of CR is different from the only report pub-
lished to date using lenalidomide in CLE. Braunstein et
al. [24] described a small cohort of five patients treated
with the same regimen for 6 weeks. At the end of treat-
ment, in that study, the majority of patients (four out of
five) achieved a partial response defined by at least a 4-
point decrease in the CLASI score, although most of
them experienced a decrease of at least 8 points [24].
Differences in treatment duration, clinical response
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Figure 2 Cutaneous Lupus Erythematosus Disease Area and
Severity Index (CLASI). CLASI shows a reduction of the CLASI
activity (CLASI A (●)) score with no significant changes in the CLASI
damage (CLASI D (■)) score over 12 months of follow-up. A significant
improvement of the inflammatory rash was already observed by week
2. Data is expressed as mean ± SEM. *P value refers to the comparison
of CLASI scores between two weeks after treatment and baseline.
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definition and follow-up between the two studies
account for the discrepancies observed. Interestingly,
this study also established for the first time preliminary
histological and biological factors associated with lenali-
domide clinical response. Whereas nonresponders had
high CXCL10 cutaneous expression and increased acti-
vated circulating CD4+ T cells, responders had reduced
glycosaminoglycan and pDCs content with a trend
toward increased circulating T regulatory cells. No cor-
relation with the IFN signature was established [24].
As with thalidomide [17], cutaneous relapse was fre-
quent and occurred in 75% of patients within 2 to 8
weeks after tapering dosage or withdrawing medication.
Although the study was not designed to establish varia-
tions in clinical response between the different histologi-
cal subtypes of CLE and few patients were included, it
was observed that whereas patients with refractory
SCLE tended to remain in remission after withdrawing
medication, those with DLE or lupus erythematosus
tumidus tended to relapse more frequently. Some of the
relapsing patients (21%) even required a low long-term
maintenance dose (5 mg/alternate days or three times a
week) to control the disease.
In the literature to date, a variety of adverse effects have
been reported, mainly in patients with haematological con-
ditions and receiving higher doses of lenalidomide. The
most commonly described include neutropenia, thrombo-
cytopenia, paraesthesia, skin and gastrointestinal toxicity,
and fatigue. Overall, myelosuppression, generally mild, has
been the most common, and although is more frequently
observed at high doses (25 to 50 mg/day), it can occur in a
dose-independent manner [18,22,23,31,32]. In our study,
lenalidomide was generally well tolerated and at this
dosage displayed a safe profile. The few observed side
effects resolved after drug withdrawal. No neurological
symptoms were reported and none of the patients with
previous thalidomide-induced polyneuropathy experienced
worsening in the repeated electrophysiological studies.
Athough increased risk of thrombosis has been previously
reported [31,32] during lenalidomide treatment, in our
study, no thrombotic events were observed. The results
need to be interpreted with caution since none of
the patients had other associated cardiovascular risk
factors, such as smoking or presence of antiphospholipid
antibodies.
Still not clear is the effect of lenalidomide on systemic
disease. Braunstein et al. described an increasing risk of
developing a severe systemic lupus flare in their small
cohort of patients with one treated patient developing a
renal flare. They attributed it to the possible effect of lena-
lidomide on T cell activation and pDCs [24]. However, no
ds
-
DN
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tit
er
 
(IU
/m
L)
A. 
Baseline After 
0
100
200
300
 
B.  
Baseline After 
60
80
100
120
140
160
Co
m
pl
em
en
t l
ev
el
s
DQ
WLE
RG
\
Figure 3 Effects of Lenalidomide on anti-dsDNA antibody and
complement levels. Comparison of anti-dsDNA antibody titres
(A) and complement levels (B) at baseline and after completing the
course of treatment.
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significant clinical or immunological effect of lenalido-
mide on systemic manifestations of SLE was observed in
our larger cohort of treated patients after 15 months of
follow-up. Only one patient with known systemic dis-
ease developed mild arthritis. None of the patients with
CLE progressed to a systemic disease and levels of anti-
dsDNA antibodies or complement remained stable dur-
ing follow-up.
Results were compared with those obtained in our pre-
vious cohort of thalidomide-treated patients [17].
Although lenalidomide was better tolerated and had a
safer profile, both agents displayed the same efficacy and
relapse rates. As lenalidomide is an analogue of thalido-
mide, the question of resistance to lenalidomide in
patients unresponsive to thalidomide arose. Both the lit-
erature [21] and our study indicate that clinical benefit
from lenalidomide can be obtained in those refractory
patients, reflecting mechanistic differences - lenalidomide
has greater immunomodulatory properties than thalido-
mide, whereas thalidomide has greater antiangiogenic
activity [20]. Lenalidomide has been found to be more
potent in the stimulation of T-cell proliferation and IFN-
gamma and IL-2 production than thalidomide, whereas
both thalidomide and pomalidomide, another thalido-
mide analogue, have been found to be more potent at
inhibiting sprout formation than lenalidomide when anti-
angiogenic properties were assessed in a human umbilical
explant model (20).
The main limitations of the study are the absence of a
randomized group control and the insufficient small sam-
ple size to draw conclusions at the histological subtype
level since the majority of included patients had DLE.
Nevertheless, the present study provides valuable infor-
mation on the critical issue of treating refractory cuta-
neous lupus lesions given the significant number of
patients studied, the relatively long period of follow-up
and the detailed clinical and laboratory information
obtained during the follow-up. Further larger controlled
trials are required to confirm our observations.
Conclusions
In conclusion, the present study confirms the efficacy
and safety of lenalidomide for refractory cutaneous
lupus disease. The benefit of lenalidomide is in reducing
disfigurement without thalidomide’s toxicity profile.
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